Status | Study |
Recruiting |
Study Name: Evaluation and Comparison of Keloids and Second Degree Burns Blisters Fluid Condition: Blisters Second Degree Burns Date: 2012-06-22 |
Completed |
Study Name: Evaluation of Three Types of Dressings After Hip Surgery Condition: Tape Blisters Hip Surgery Date: 2011-11-04 Interventions: Device: Dressing of wound The |
Completed |
Study Name: Imaging of Trabeculectomy Blebs Using the Spectral Domain Optical Coherence Tomography Condition: Glaucoma Filtering Blebs Date: 2011-07-08 Interventions: Procedure: trabeculectomy postoperative imaging of trabeculectomy blebs with the spectral domain optical |
Completed |
Study Name: Prevention Trial Assessing Paper-Tape in Endurance Distances (PreTAPED) Condition: Blister Date: 2010-05-07 Interventions: Procedure: Paper tape Paper tape assigned to each participant's randomly selected foot. |
Completed |
Study Name: Blister Packaging Medication to Increase Treatment Adherence and Clinical Response Condition: Medication Adherence Accidental Overdose Deliberate Overdo Date: 2010-05-04 Interventions: Other: Blister packaging medications |
Completed |
Study Name: Hydrogel Blister Patch Prototype Treatment for Foot Blisters on the Heel Condition: Blister Date: 2010-03-16 Interventions: Device: Experimental Blister Patch |
Completed |
Study Name: Artemether-Lumefantrine (AL) Unit Dose Pre-packs Versus Blister Packs Condition: Malaria Date: 2010-02-08 Interventions: Drug: AL Blister-packs with Instruction leaflets |
Completed |
Study Name: Cantharidin-induced Skin Blister for Testing Anti-inflammatory Effects of Macrolides Condition: Inflammation Date: 2009-12-03 Interventions: Other: Cantharidin Cantharone |
Recruiting |
Study Name: An Exploratory Evaluation of Biomarkers in Blister Fluid in Healthy Volunteers and Irradiated Skin Condition: Breast Cancer Healthy Volunteer Prostate Cancer Date: 2009-06-17 |
Completed |
Study Name: Subconjunctival Bevacizumab Effect on Bleb Vascularity Condition: Bleb Vascularity Bleb Fibrosis Date: 2009-03-01 Interventions: Drug: Bevacizumab sub-conjunctival injection of 1.25mg Bevacizumab |